Amylin completes application to FDA for metreleptin for Lipidostrophy

Amylin has completed its biologics license application with the FDA for metreleptin � an analogue of the human hormone leptin, which is under investigation to treat lipodystrophy. Lipidosytophy patients lack the required fat tissue for normal metabolic function. A lack of fat tissue can lead to relative deficiency of leptin, which is needed to help the metabolic system function properly to regulate food intake and the storage and break-down of dietary fat and carbohydrates. As a result, fat accumulates in the blood and organs, such as liver and muscle, which can lead to life-threatening complications, including insulin-resistant diabetes, hypertriglyceridemia, acute pancreatitis and hepatic steatosis or steatohepatitis, also known as fatty-liver disease.